Single-Use Bioprocessing Industry Overview

The global single-use bioprocessing market was valued at USD 27.94 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 16.24% from 2024 to 2030. The adoption of single-use bioprocessing technology is driven by the growing demand for biopharmaceuticals over the past few years, along with an increase in investments for the development of biologics, such as monoclonal antibodies, vaccines, recombinant proteins, and others. Furthermore, benefits pertaining to the use of single-use technology, such as significant reduction in costs and time required for operations & facility construction have supported the implementation of single-use systems in the bioprocessing sector.

Gather more insights about the market drivers, restrains and growth of the Single-Use Bioprocessing Market

The COVID-19 pandemic has generated new growth opportunities for key stakeholders in the industry. Key biopharmaceutical players can leverage the opportunity by expanding their COVID-19-related product offerings by scaling up their production facilities with the implementation of single-use bioprocessing equipment. A significant number of biopharmaceutical companies are actively involved in the development & production of COVID-19 vaccines. These programs are majorly based on single-use technologies as these systems are flexible, cost-effective, and reduce the risk of cross-contamination.

Such an ongoing and continuous increase in the adoption of these bioprocessing systems due to the COVID-19 pandemic is anticipated to drive industry growth. The commercial success of biopharmaceuticals has led single-use manufacturers to expand their production facilities globally. Capacity expansion projects have been a part of many manufacturers’ multi-year plans, to leverage a global reach and a broader customer base. For instance, in December 2020, Merck KGaA invested over USD 42 million to broaden its existing manufacturing facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire, U.S.

This expansion was aimed at enhancing the company’s single-use assembly operations along with other product portfolios. Furthermore, with the rising focus on the development of regenerative medicine, such as cell and gene therapies, increased success of clinical trials, and enhanced rate of regulatory approvals, demand for commercialization of these products is expected to grow in the near future. In addition, owing to the increasing outsourcing activities in biopharmaceutical manufacturing, CMOs are adopting single-use systems for maintaining highly dynamic and frequently changing product portfolios.

Consequently, the extensive implementation of single-use systems in CMOs across the globe is likely to boost industry growth. For instance, in July 2021, Pall Corp. signed a contract with Exothera S.A., a CDMO, to establish a manufacturing space using Allegro STR single-use bioreactors and other technologies. Although innovations in single-use technology are the current trend for the bioprocessing industry, the technology has still not completely displaced stainless steel reusable systems. High-volume biopharmaceutical product manufacturers continue to fixate on the multi-use system due to their feasibility at large scales. This represents a significant challenge for the industry's growth.

Browse through Grand View Research's Biotechnology Industry Research Reports.

  • The global clinical trials market size was valued at USD 80.7 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.49% from 2024 to 2030.
  • The global biologics market size was valued at USD 461.74 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 10.3% from 2023 to 2030.

Single-Use Bioprocessing Market Segmentation

Grand View Research has segmented the global single-use bioprocessing market based on product, workflow, end-use, and region:

Single-use Bioprocessing By Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Simple & Peripheral Elements
    1. Tubing, Filters, Connectors, & Transfer Systems
    2. Bags
    3. Sampling Systems
    4. Probes & Sensors
      1. pH Sensor
      2. Oxygen Sensor
      3. Pressure Sensors
      4. Temperature Sensors
      5. Conductivity Sensors
      6. Flow Sensors
      7. Others
    5. Others
  • Apparatus & Plants
    1. Bioreactors
      1. Upto 1000L
      2. Above 1000L to 2000L
      3. Above 2000L
    2. Mixing, Storage, & Filling Systems
    3. Filtration System
    4. Chromatography Systems
    5. Pumps
    6. Others
  • Work Equipment
    1. Cell Culture System
    2. Syringes
    3. Others

Single-use Bioprocessing By Workflow Outlook (Revenue, USD Million, 2018 - 2030)

  • Upstream Bioprocessing
  • Fermentation
  • Downstream Bioprocessing

Single-use Bioprocessing By End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Biopharmaceutical Manufacturers
    1. CMOs & CROs
    2. In-house Manufacturers
  • Academic & Clinical Research Institutes

Single-use Bioprocessing Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America
    1. U.S.
    2. Canada
  • Europe
    1. UK
    2. Germany
    3. France
    4. Italy
    5. Spain
    6. Denmark
    7. Sweden
    8. Norway
  • Asia Pacific
    1. Japan
    2. China
    3. India
    4. South Korea
    5. Australia
    6. Thailand
  • Latin America
    1. Brazil
    2. Mexico
    3. Argentina
  • Middle East and Africa (MEA)
    1. South Africa
    2. Saudi Arabia
    3. UAE
    4. Kuwait

Key Companies profiled:

  • Sartorius AG
  • Danaher
  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Avantor, Inc.
  • Eppendorf SE
  • Corning Incorporated
  • Lonza
  • PBS Biotech, Inc.
  • Meissner Filtration Products, Inc.

Recent Developments

  • In January 2024, CDMO AGC Biologics announced a growth strategy to develop pharmaceutical manufacturing capabilities in the Asia region through the expansion of their mammalian cell culture, mRNA and cell therapy facility in Japan. This development is aimed to support the global demand for biologics and advanced therapy medicinal products.
  • In September 2023, Getinge launched a single-use bioreactor named the AppliFlex ST GMP. The new product is available in different sizes and provides a comprehensive cGMP manufacturing solution for mRNA production and cell and gene therapies.
  • In April 2023, Merck KGaA launched Ultimus, a single-use process container film, to provide superior strength & leak resistance for single-use assemblies.

Order a free sample PDF of the Single-Use Bioprocessing Market Intelligence Study, published by Grand View Research.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com

Follow Us: LinkedIn | Twitter